{"brief_title": "A Clinical Efficacy Study Of An Oral Tyrosine Kinase Inhibitor Of VEGFR-2 Given In Combination With Chemotherapy", "brief_summary": "The purpose of this study is to determine whether CP-547,632, an oral VEGFR-2 tyrosine kinase inhibitor when given in combination with chemotherapy (carboplatin and paclitaxel) is effective in the treatment of advanced stage non-small cell lung cancer.", "condition": ["Lung Neoplasms"], "intervention_type": ["Drug"], "intervention_name": ["CP-547,632"], "criteria": "Inclusion Criteria: - Histologically or cytologically confirmed stage IIIB (inicluding those with pleural effusion), IV or recurrent non-small cell lung cancer (nsclc). - Bidimensionally measurable disease >2cm x 1 cm by conventional CT Scan or >1 cm x 1cm by spiral CT Scan. Exclusion Criteria: - No tumors in close proximity to major veins or arteries. - No sanguinous pleural effusion due to disease or pericardial effusion suspicious for disease. - No evidence or history brain metastases.", "gender": "All", "minimum_age": "18 Years", "maximum_age": "N/A", "healthy_volunteers": "No", "mesh_term": ["Lung Neoplasms"], "id": "NCT00074854"}